Weight loss pills—ranging from prescription GLP-1/GIP agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to older agents like phentermine, orlistat, naltrexone/bupropion (Contrave), and liraglutide (Saxenda), as well as over-the-counter supplements and research peptides—can interact with a wide range of other medications, sometimes with serious consequences. By 2026 these interactions are better documented than ever, […]

Peptides have emerged as one of the most dynamic tools in metabolic research and weight management protocols by 2026. These short chains of amino acids act as targeted signalling molecules, mimicking or amplifying natural hormones, growth factors, and regulatory pathways that directly influence energy expenditure, fat oxidation, insulin sensitivity, appetite control, and body composition. Unlike […]